Overall, cancer patients with different molecular features were compared in various ways, by often taking into consideration heterogeneous criteria for comparisons (e.g., HER2+ vs. HER2-; HER2+ vs. TNBC; Luminal vs. TNBC; Luminal vs. healthy controls; pre-therapy vs. post-therapy). The gene discussed is ERBB2; the disease is cancer.